Blinatumomab
Details of the Drug
- Generic Name:
- Blinatumomab
- Pronunciation:
- blin-a-TOOM-oh-mab
- Drug Type:
- Bispecific
- How the Drug is Given:
Intravenously (IV)
- Names:
- Blincyto®
- Blinatumomab
Indications and Usage
Blinatumomab is FDA approved for the treatment of adult and pediatric patients one month and older with:
- CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
- Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).
- CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.
Side effects needing medical attention
The most common adverse reactions are fever, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.